



Recommendations for Parkinson's clinical trials using digital health technologies

Kimberly Ward Barowicz, BS, CAPM, SHRM-CP¹, Marjan Meinders, PhD², Mark Frasier, PhD³, Johan Hellsten, PhD^{4#}, Tairmae Kangarloo, BS⁵, Matthew Sullivan, PhD^{6#}, Cindy Zadikoff, MD⁷, Martijn Müller¹, PhD, Diane Stephenson¹, PhD

¹ Critical Path Institute, Tucson, AZ. USA, ² Radboud university medical center, Nijmegen, Netherlands, ³ The Michael J. Fox Foundation, New York, NY, USA, ⁴ H. Lundbeck A/S, Valby, Denmark, ⁵ Takeda Pharmaceuticals, Lexington, MA, USA⁶ Parkinson's UK, London, England, ⁷ AbbVie Inc., North Chicago, IL, USA, [#]Person with Parkinson's

- Critical Path for Parkinson's consortium's Digital Drug Development Tool (3DT) initiative is a global precompetitive collaboration to advance digital health technologies (DHT) in Parkinson's.
- 3DT led a task force and produced recommendations and considerations for integrating digital health technologies in Parkinson's clinical studies, prioritizing a participant-centered perspective.
- The work of this collaboration places people with Parkinson's at the center of study design, emphasizing their involvement and needs in the development and implementation of digital health technologies.

Critical Path for Parkinson's


Digital Drug

Development

Tools Initiative

(3DT)

Incorporating the lived of experience is key to expediting the approval of much-needed treatments for individuals with Parkinson's



Izmailova ES, AbuAsal B, Hassan HE, Saha A, Stephenson D. Digital technologies: Innovations that transform the face of drug development. Clin Transl Sci. 2023

May 8. doi: 10.1111/cts.13533. Epub ahead of print. PMID: 37157935.

Unveiling insights Unique challenges sensors, etc.), requ

Unique challenges arise with the inclusion of DHT (smart phones, sensors, etc.), requiring a comprehensive understanding of participant experiences



The time is now

Digital technologies are increasingly integrated into Parkinson's clinical trials and there is a sense of urgency to adapt to this emerging need



Maximize efficiency

Optimized studies can accelerate the path and minimize resource-intensive delays



Task Force Outcome

Recommendations in 3 key areas:

Protocol Design Recruitment & Enrollment

Protocol Compliance & Participant Retention



View 3DT's recommendations for clinical trial design

When using digital health technologies for assessing motor fluctuations or fatigue in Parkinson's, consider tailoring assessments, minimizing burden, and accounting for daily life impact, study duration, frequency of assessments, cultural/socio-economic factors, and the overall lived experience.



View the video poster presentation here